PD‑1/PD‑L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta‑analysis of randomized trials
- Authors:
- Maria Saveria Rotundo
- Vincenzo Bagnardi
- Miryam Rotundo
- Mario Comandè
- Maria Giulia Zampino
-
Affiliations: Complex Operative Unit of Medical Oncology, Uboldo Hospital, Cernusco Sul Naviglio, I‑20063 Milan, Italy, Department of Statistics and Quantitative Methods, University of Milan‑Bicocca, I‑20126 Milan, Italy, Department of Experimental and Clinical Medicine‑Medical, Veterinary and Pharmaceutical Biotechnologies, Magna Graecia University of Catanzaro, I‑88100 Catanzaro, Italy, Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, I‑20141 Milan, Italy - Published online on: February 23, 2022 https://doi.org/10.3892/ol.2022.13254
- Article Number: 134
-
Copyright: © Rotundo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Cervantes A, Nordlinger B and Arnold D; ESMO Guidelines Working Group, : Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Biller LH and Schrag D: Diagnosis and treatment of metastatic colorectal cancer: A review. JAMA. 325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 306:752–755. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J and Giles F: Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer: Lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 6:392018. View Article : Google Scholar : PubMed/NCBI | |
|
Stein A, Moehler M, Trojan J, Goekkurt E and Vogel A: Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Crit Rev Oncol Hematol. 130:13–26. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Boland CR and Goel A: Microsatellite instability in colorectal cancer. Gastroenterology. 138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, et al: Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology. 133:48–56. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kawakami H, Zaanan A and Sinicrope FA: Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 16:302015. View Article : Google Scholar : PubMed/NCBI | |
|
Catalano I, Grassi E, Bertotti A and Trusolino L: Immunogenomics of colorectal tumors: Facts and hypotheses on an evolving Saga. Trends Cancer. 5:779–788. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Marcus L, Lemery SJ, Keegan P and Pazdur R: FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 25:3753–3758. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, Neyns B, Leach JL, Garcia Alfonso P, Lee JJ, et al: Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. J Clin Oncol. 35 (Suppl 4):S5192017. View Article : Google Scholar | |
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Durable clinical benefit with Nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse M, Van Cutsem E, McDermott RS, Hill AG, et al: Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. J Clin Oncol. 37 (Suppl 4):S6352019. View Article : Google Scholar | |
|
Lenz HJJ, Van Cutsem E, Limon ML, Wong KY, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Luppi G, Cardin D, et al: Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann Oncol. 29:viii7142018. View Article : Google Scholar : PubMed/NCBI | |
|
Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith DM, Garcia-Carbonero R, Alcaide J, Gibbs P, et al: Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 39 (Suppl 15):S35002021. View Article : Google Scholar | |
|
Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group, : Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI | |
|
Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ and Koffel JB; PRISMA-S Group, : PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 10:392021. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Freites-Martinez A, Santana N, Arias-Santiago S and Viera A: Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112:90–92. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Softw. 36:1–48. 2010. View Article : Google Scholar | |
|
R Core Team R, . A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2014.http://www.R-project.org/ | |
|
O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, et al: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 12:e01898482017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HT, Lee SH and Heo YS: Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules. 24:11902019. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, et al: Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 38:11–19. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shiu KK, Andre T, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith DM, Garcia-Carbonero R, Benavides M, Gibbs P, et al: KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 39 (Suppl 3):S62021. View Article : Google Scholar | |
|
Callahan MK, Odunsi K, Sznol M, Nemunaitis JJ, Ott PA, Dillon PM, Park AJ, Schwarzenberger P, Ricciardi T, Macri MJ, et al: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. J Clin Oncol. 35 (Suppl 15):S30692017. View Article : Google Scholar | |
|
Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, et al: Effect of combined immune checkpoint inhibition vs. best supportive care alone in patients with advanced colorectal cancer: The Canadian Cancer Trials Group CO.26 study. JAMA Oncol. 6:831–838. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, et al: The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 21:1639–1651. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH Jr, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, et al: Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 30:1134–1142. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, et al: Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20:849–861. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Schmoll HJ, Arnold D, De Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, et al: MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: An adaptable signal-seeking approach. J Cancer Res Clin Oncol. 144:1197–1204. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grothey A, Tabernero J, Arnold D, De Gramont A, Ducreux MP, O'Dwyer PJ, Van Cutsem E, Bosanac I, Srock S, Mancao C, et al: Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs. FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL-a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol. 29:VIII714–VIII715. 2018. View Article : Google Scholar | |
|
Mettu NB, Twohy E, Ou FS, Halfdanarson TR, Lenz HJ, Breakstone R, Boland PM, Crysler O, Wu C, Grothey A, et al: BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study. Ann Oncol. 30:v2032019. View Article : Google Scholar | |
|
Messersmith WA: NCCN Guidelines Updates: Management of metastatic colorectal cancer. J Natl Compr Canc Netw. 17:599–601. 2019.PubMed/NCBI | |
|
Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kyi C and Postow MA: Immune checkpoint inhibitor combinations in solid tumors: Opportunities and challenges. Immunotherapy. 8:821–837. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Overman MJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, et al: NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC). J Clin Oncol. 39 (Suppl 3):TPS1582021. View Article : Google Scholar | |
|
Sinicrope FA, Ou FS, Zemla T, Nixon AB, Mody K, Levasseur A, Dueck AC, Dhanarajan AR, Lieu CH, Cohen DJ, et al: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502). J Clin Oncol. 37 (Suppl 15):e151692019. View Article : Google Scholar | |
|
He S, Hu D, Feng H, Xue Y, Jin J and Wang X: Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: A meta-analysis. J Comp Eff Res. 9:1285–1292. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xie YH, Chen YX and Fang JY: Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI | |
|
Wan L, Wang Z, Xue J, Yang H and Zhu Y: Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: A meta-analysis. Transl Cancer Res. 9:5437–5449. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al: Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 30:1096–1103. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Parikh AR, Clark JW, Wo JYL, Yeap BY, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio BJ, Weekes CD, Zhu AX, et al: A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). J Clin Oncol. 37 (Suppl 15):S35142019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JJ, Yothers G, George TJ, Fakih M, Basu Mallick A, Maalouf BN, Krauss JC, Heron DE, Allegra CJ and Jacobs SA: NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy. J Clin Oncol. 36 (Suppl 15):e156812018. View Article : Google Scholar | |
|
Monjazeb A, Giobbie-Hurder A, Lako A, Tesfaye AA, Stroiney A, Gentzler RD, Jabbour S, Alese OB, Rahma OE, Cleary JM, et al: Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation. J Clin Oncol. 37 (Suppl 8):S492019. View Article : Google Scholar | |
|
A Phase Ib study to evaluate the safety, efficacy, pharmacokinetics of cibisatamab in combination with atezolizumab after pretreatment with obinutuzumab in participants with previously treated metastatic colorectal adenocarcinoma. ClinicalTrials.gov Identifier. NCT03866239. Other Study ID Numbers: CO40939; EudraCT Number: 2018-003198-93. https://clinicaltrials.gov/ct2/show/NCT03866239March 31–2021 | |
|
Martinelli E, Troiani T, Cardone C, Ciardiello D, Zanaletti N, Borrelli C, Terminiello M, Avallone A, Falcone A, Maiello E, et al: Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon. Ann Oncol. 30:v2512019. View Article : Google Scholar | |
|
Stein A, Binder M, Goekkurt E, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Doerfel S, Al-Batran SE, Karthaus M, et al: Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 38 (Suppl 4):S962020. View Article : Google Scholar | |
|
Van Den Eynde M, Huyghe N, De Cuyper A, Sinapi I, Ferrier M, Gilet M, Van Maanen A, Castella ML, Galon J and Carrasco J: Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)-A proof of concept, open-label, non-randomized phase IIa study. J Clin Oncol. 39 (Suppl 3):S802021. View Article : Google Scholar | |
|
Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, et al: Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: Challenges and future perspectives. Ann Oncol. 31:30–40. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Damato A, Berselli A, Iachetta F, Romagnani A, Larocca M, Garcia Arias A, Antonuzzo L, Nasti G, Bergamo F and Pinto C: Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated. J Clin Oncol. 39 (Suppl 3):S372021. View Article : Google Scholar | |
|
Antoniotti C, Borelli B, Rossini D, Pietrantonio F, Morano F, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, et al: AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer. 20:6832020. View Article : Google Scholar : PubMed/NCBI | |
|
Cousin S, Bellera CA, Guégan JP, Gomez-Roca CA, Metges JP, Adenis A, Pernot S, Cantarel C, Kind M, Toulmonde M, et al: REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors-Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort. J Clin Oncol. 38 (Suppl 15):S40192020. View Article : Google Scholar | |
|
Siena S, Sartore-Bianchi A, Personeni N, Pietrantonio F, Germano G, Amatu A, Bonoldi E, Valtorta E, Barault L, Di Nicolantonio F, et al: Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. J Clin Oncol. 37 (Suppl 15):TPS26592019. View Article : Google Scholar | |
|
Nivolumab Plus Ipilimumab, Temozolomide in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (MAYA). ClinicalTrials.gov Identifier. NCT03832621. Other Study ID Number: INT202-18. https://clinicaltrials.gov/ct2/show/NCT03832621March 31–2021 | |
|
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients with Advanced Solid Tumors (DAPPER). ClinicalTrials.gov Identifier. NCT03851614. Other Study ID Number: DAPPER-001. https://clinicaltrials.gov/ct2/show/NCT03851614March 31–2021 | |
|
Tintelnot J and Stein A: Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World J Gastroenterol. 25:3920–3928. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huyghe N, Baldin P and Van Den Eynde M: Immunotherapy with immune checkpoint inhibitors in colorectal cancer: What is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf). 8:11–24. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee WS, Yang H, Chon HJ and Kim C: Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 52:1475–1485. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesh S, Shui X, Craig KP, Park J, Wang W, Brown BD and Abrams MT: RNAi-Mediated beta-catenin inhibition promotes T cell infiltration and antitumor activity in combination with immune checkpoint blockade. Mol Ther. 26:2567–2579. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, et al: CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 24:4785–4797. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, et al: Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Dig Liver Dis. 53:318–323. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Pascual J, Ayuso-Sacido A and Belda-Iniesta C: Drug resistance in cancer immunotherapy: New strategies to improve checkpoint inhibitor therapies. Cancer Drug Resist. 2:980–993. 2019. | |
|
Ghiringhelli F and Fumet JD: Is there a place for immunotherapy for metastatic microsatellite stable colorectal cancer? Front Immunol. 10:18162019. View Article : Google Scholar : PubMed/NCBI | |
|
Shan T, Chen S, Wu T, Yang Y, Li S and Chen X: PD-L1 expression in colon cancer and its relationship with clinical prognosis. Int J Clin Exp Pathol. 12:1764–1769. 2019.PubMed/NCBI | |
|
Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, et al: Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: A retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 1:207–216. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsantoulis P, Hill LA, Walker SM, Wirapati P, Graham DM, Wilson RH, Coyle V, Delorenzi M, HarkinD P, Kennedy RD and Tejpar S: Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers. J Clin Oncol. 34:30352016. View Article : Google Scholar | |
|
Sun G, Dong X, Tang X, Qu H, Zhang H and Zhao E: The prognostic value of immunoscore in patients with colorectal cancer: A systematic review and meta-analysis. Cancer Med. 8:182–189. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al: Two FOXP3(+) CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22:679–684. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Spallanzani A, Gelsomino F, Caputo F, Santini C, Andrikou K, Orsi G, Rimini M, Pipitone S, Riggi L, Bardasi C, et al: Immunotherapy in the treatment of colorectal cancer: A new kid on the block. J Cancer Metastasis Treat. 4:282018. View Article : Google Scholar |
